Rana Al-Hallaq, PHD is DDF’s Pfizer SAB Representative.
At Pfizer Ventures, Rana is a Senior Director, WWBD and Principal. She is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. Rana joined Pfizer in 2015 as an Early Candidate Clinical Lead where she advised early clinical programs in CNS to ensure alignment with business strategies.. Prior to joining Pfizer, she held roles at Allergan (formerly Actavis, formerly Forest Laboratories), first in Clinical Development Psychiatry as scientific and operational lead on Phase 2 and Phase 3 studies investigating novel treatments for Major Depressive Disorder and schizophrenia, and later in Business Development where she assessed and executed on a number of acquisitions and licenses across therapeutic areas.
Rana received her BA in Biology from Hamilton College and holds a PhD in Neuroscience from Georgetown University Medical Center.
